RxDoctor Payments Data

Mazen Ganim, MD

Interventional Cardiology · Humble, TXNPI 1740398577

Payments from drug & device makers

$16,991in general payments, 2019–2025

Across 711 payments — averaging $23.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Abbott$2K
  • Novartis$2K
  • Merck$936
  • E.r. Squibb & Sons, L.L.C.$850
  • Amgen$796
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$16,77299%
  • Education$2191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific90$2,467
Abbott32$2,089
Novartis99$1,513
Merck50$936
E.r. Squibb & Sons, L.L.C.44$850
Amgen46$796
Bard Peripheral Vascular, Inc.23$724
Johnson & Johnson48$695
Amarin Pharma, Inc.31$521
Pfizer23$484
Heartflow, Inc.13$418
Sanofi-aventis U.S. LLC25$402
Cvrx, Inc.4$386
Impulse Dynamics (USA) Inc.7$371
Novo Nordisk19$336
Kestra Medical Technology Services, Inc.4$333
AstraZeneca16$330
Esperion Therapeutics, Inc.20$315
Astellas Pharma US Inc9$307
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)13$253
Cardiovascular Systems Inc.6$220
Silk Road Medical, Inc.1$209
Boehringer Ingelheim6$195
Shockwave Medical, Inc2$172
Medtronic(2 entities)7$142
Atricure, Inc.5$133
Tactile Systems Technology Inc9$115
Canon Medical Systems USA, Inc.3$99
Regeneron Healthcare Solutions, Inc.6$94
Angiodynamics, Inc.5$94
Bridgebio Pharma, Inc.3$78
Regeneron2$65
Cardiva Medical, Inc.2$64
Bayer3$63
Biotronik Inc.3$63
Cook Medical LLC3$58
Biom'up France SAS2$47
Scpharmaceuticals Inc.2$46
Biosense Webster, Inc.1$41
Chiesi USA, Inc.2$40
Infobionic, Inc1$36
Philips North America LLC1$34
Edwards Lifesciences1$32
Alnylam Pharmaceuticals Inc.1$27
Althera Pharmaceuticals LLC2$27
Coala Life Inc1$24
Agepha Pharma FZ LLC1$23
Actelion Pharmaceuticals US, Inc.1$22
Itamar Medical Inc1$20
United Imaging Healthcare North America LLC1$19
Inspire Medical Systems, Inc.1$18
Lexicon Pharmaceuticals, Inc.1$17
Altathera Pharmaceuticals LLC1$17
Irhythm Technologies, Inc.1$16
Teleflex LLC1$16
Kowa Pharmaceuticals America, Inc.1$15
Osprey Medical Inc1$14
Kiniksa Pharmaceuticals International, PLC1$13
BD1$13
Arbor Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,991 in reported general payments places this provider in the 60th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$332,172
Medicare patients
766
Services billed
6,773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban289$370,334
XareltoRivaroxaban120$165,652
Repatha SureclickEvolocumab153$154,810
EntrestoSacubitril/Valsartan75$119,873
OzempicSemaglutide54$70,137
BrilintaTicagrelor71$69,125
Repatha SyringeEvolocumab30$39,157
FarxigaDapagliflozin Propanediol16$21,140
VascepaIcosapent Ethyl27$18,633
Praluent PenAlirocumab12$17,411
Metoprolol Succinate912$15,437
Rosuvastatin Calcium724$12,131
JardianceEmpagliflozin11$10,601
Ezetimibe271$9,159
Atorvastatin Calcium827$8,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$484$370,334289 claims
Johnson & JohnsonXarelto$695$165,652120 claims
NovartisEntresto$1,513$119,87375 claims
AstraZenecaBrilinta, Farxiga$330$90,26587 claims
Novo NordiskOzempic$336$70,13754 claims
Boehringer IngelheimJardiance$195$10,60111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Humble

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →